Universitätsklinikum Düsseldorf

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany (2020) Hübner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Journal article Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial (2020) de Gregorio A, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, et al. Journal article Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany (2020) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article Update Breast Cancer 2020 Part 3 - Early Breast Cancer (2020) Huober J, Schneeweiss A, Hartkopf AD, Müller V, Lux MP, Janni W, Ettl J, et al. Journal article, Review article Treatment landscape and prognosis after treatment with trastuzumab emtansine (2020) Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, et al. Journal article Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer (2020) Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, et al. Journal article, Review article S2k-Leitlinie: Management der Großgefäßvaskulitiden (2020) Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, et al. Journal article, Review article S2k-Leitlinie (Kurzfassung): Management der Großgefäßvaskulitiden (2020) Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, et al. Journal article, Review article Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020) Laakmann E, Witzel I, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mobus V, et al. Conference contribution Use of a molecular Registry (PRAEGNANT) for Patient-Selection and Biomarker-Analysis for the SHERBOC Study (2020) Hübner H, Kurbacher C, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Conference contribution